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Since 2010, when the Spanish Society for Medical
Oncology (SEOM) started publishing clinical practice
guidelines for the management of solid tumours and sup-
portive care, the challenges have evolved from educational
purposes to policy purposes. Due to our increasingly
complex system, patient care requires cohesive documents
on which to base daily decisions [1–3] and SEOM is really
committed to working on balancing both sustainability and
equity in the access to new treatment options.
The aim of the guidelines was to combine updates of
common tumours as well as to introduce new issues. This
is one the reasons that explains their success as a con-
solidated project [4]. In the current edition, an indepen-
dent external committee has been added to ensure the
utmost rigour based on the level of evidence and grades
of recommendations while maintaining their high prac-
tical value. There is no doubt that this decision will
increase their value.
The nine guidelines to be published include highly rel-
evant topics such as prevention and screening, hydroelec-
trolitic disorders, prostate cancer, management of
thromboembolic events, renal cancer, gastroenteropancre-
atic neuroendocrine tumours, thyroid cancer, ovarian
tumours and cancer of unknown origin.
While earlier diagnosis and advances in treatment have
considerably improved survival in recent years, further
progress is needed. In the light of the current status of
knowledge, primary and secondary prevention of the most
prevalent neoplasms (breast, cervix, prostate, colon and
lung) are reviewed by SEOM experts. One of the greatest
challenges is the fact that current therapies for advanced
diseases are not curative, necessitating treatment over a
number of years and placing a significant health care bur-
den on society. To reduce this burden, care delivery must
be more efficient and cost-effective. In particular, devel-
opments of adequate screening programs are needed, along
with preventative strategies [5].
This is the first time that guidelines on hydroelectrolytic
disorders have been included. We are aware of the
importance acquired by some recent advances in this field
and the need for comprehensive training in symptoms
common to different tumours [6]. Similarly, a review of the
management of thromboembolic events has also been
considered. Venous thromboembolic events in oncological
patients are very common and have specific challenges.
These guidelines summarise the most recent recommen-
dations about prophylaxis and treatment of these events, as
well as help to address some doubts about specific clinical
problems [7].
The options for patients with prostate cancer have
recently increased with the addition of several new treat-
ments that need to be analysed from a medical oncology
perspective [8]. Similarly, the approaches to the available
options for renal cancers have been updated [9].
Gastroenteropancreatic Neuroendocrine Neoplasms are
a challenging family of tumours of growing incidence
and varied clinical management. Significant advances in
the diagnosis and the understanding of the molecular
biology of these tumours have been achieved. Diagnostic
workup, histological and staging classifications and the
different available therapeutic approaches are briefly
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discussed in the manuscript from a practical point of
view [10].
A further example of recent advances in the diagnosis,
molecular biology and systemic therapeutics is thyroid
cancer. This is the reason why new recommendations have
been considered necessary [11]. Treatment options for the
management of ovarian carcinoma have been also updated,
including the most recent findings regarding their biology
and new targeted therapies [12].
Last but not least, we still have the challenge of man-
aging patients with ‘‘cancer of unknown origin’’. This is a
constantly changing area where a delicate balance is con-
tinuously needed. SEOM guidelines are intended to help
oncologists in making their decisions [13].
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